Date: 2015-09-01
Type of information: Resignation
Compound:
Company: Neurovive Pharmaceutical (Sweden)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On September 1, 2015, NeuroVive Pharmaceutical, the mitochondrial medicine company, announced a change in leadership of the company. Mikael Brönnegård will no longer serve as Chief Executive Officer. The Board is pleased to announce that NeuroVive’s COO Jan Nilsson, who has extensive experience at senior levels within international pharmaceutical companies, will take over as interim CEO. The recruitment process to find a successor has begun and the company’s COO Jan Nilsson will head up the company in the role of interim CEO in the period until a new CEO is appointed by the Board of Directors.
Financial terms:
Latest news:
